Search results
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 6 days agoProgression-free survival is how long patients live before their cancer worsens. The company added...
BMS secures another EC approval for Opdivo combination
Pharmaceutical Technology via Yahoo Finance· 6 days agoPreviously, there were no marketed therapies that improved overall survival in patients with...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 1 day agoThe treatment, called Krazati, was little better than standard chemotherapy in a study enrolling...Oncology meeting. Patients who received Bristol’s pill lived a median of 5.5 months before ...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 3 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 6 days agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Gilead’s Trodelvy misses goal in bladder cancer study
BioPharma Dive via Yahoo Finance· 4 days agoTreatment didn’t significantly improve overall survival in the trial, a finding that one analyst...
G1 Therapeutics seeks partner to advance cancer treatment - Triangle Business Journal
The Business Journals· 5 days agoA biopharmaceutical company in Research Triangle Park is looking for a partner to advance one of its...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoPhase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line ...
Burkina Faso named most neglected crisis for second year in a row
KOAM· 23 hours agoNine out of the 10 most neglected crises outlined in the report were in Africa, with Cameroon, Central African Republic, Mali, and Niger holding the second to fifth positions respectively. The ...
Gilead's Trodelvy fails to meet main goal in late-stage cancer study
Reuters· 5 days agoShares of Gilead fell 3.3% in extended trade after the company said the drug did not meet the main...